New hope for advanced breast cancer: drug combo trial launches
NCT ID NCT07163481
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a drug called sacituzumab govitecan combined with hormone therapy in 12 people with HR-positive, HER2-negative metastatic breast cancer that has worsened after CDK4/6 inhibitor treatment. The main goal is to check safety and side effects, while also looking at how well the tumors shrink. It is a small, first-in-human combination study, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab govitecan (a drug that targets cancer cells) combined with endocrine therapy (fulvestrant, anastrozole, or exemestane)
- What this could lead to
- If successful, this could point toward a new combination treatment option for people with advanced breast cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a very early, small Phase Ib trial with only 12 participants, focused mainly on safety. The combination may not prove effective or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New decision tool aims to ease tough talks for advanced breast cancer patients
- Which drug first? new study aims to improve breast cancer treatment order
- New combo shows promise for aggressive breast cancer
- New combo therapy aims to slow advanced breast cancer in patients who relapsed
- Blood test could help personalize breast cancer therapy
- Real-World data reveals how breast cancer patients fare after initial therapy